Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

被引:4
|
作者
Watase, Mayuko [1 ]
Mochimaru, Takao [1 ,2 ]
Kawase, Honomi [1 ]
Shinohara, Hiroyuki [1 ]
Sagawa, Shinobu [1 ]
Ikeda, Toshiki [1 ]
Yagi, Shota [1 ]
Yamamura, Hiroyuki [1 ]
Matsuyama, Emiko [1 ]
Kaji, Masanori [1 ]
Kurihara, Momoko [1 ]
Sato, Midori [1 ]
Horiuchi, Kohei [1 ]
Watanabe, Risa [1 ]
Nukaga, Shigenari [1 ]
Irisa, Kaoru [1 ]
Satomi, Ryosuke [1 ]
Oyamada, Yoshitaka [1 ,2 ]
机构
[1] Natl Hosp Org Tokyo Med Ctr, Dept Resp Med, Tokyo, Japan
[2] Natl Hosp Org Tokyo Med Ctr, Dept Allergy, Tokyo, Japan
来源
PLOS ONE | 2023年 / 18卷 / 03期
关键词
PULMONARY-FIBROSIS;
D O I
10.1371/journal.pone.0283288
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
No biomarkers have been identified in bronchoalveolar lavage fluid (BALF) for predicting fibrosis progression or prognosis in progressive fibrosing interstitial lung disease (PF-ILD). We investigated BALF biomarkers for PF-ILD diagnosis and prognosis assessment. Overall, 120 patients with interstitial pneumonia who could be diagnosed with PF-ILD or non PF-ILD were enrolled in this retrospective study. PF-ILD was diagnosed according to Cottin's definition. All patients underwent bronchoscopy and BALF collection. We evaluated blood and BALF parameters, high-resolution computed tomography (HRCT) patterns, and spirometry data to identify factors influencing PF-ILD diagnosis and prognosis. On univariate logistic analysis, age, sex, the BALF white blood cell fraction (neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio), BALF flow cytometric analysis (CD8), and an idiopathic pulmonary fibrosis/usual interstitial pneumonia pattern on HRCT were correlated with PF-ILD diagnosis. Multivariate logistic regression analysis revealed that sex (male), age (cut-off 62 years, area under the curve [AUC] 0.67; sensitivity 0.80; specificity 0.47), white blood cell fraction in BALF (NLR, neutrophil, and lymphocyte), and CD8 in BALF (cut-off 34.2; AUC 0.66; sensitivity, 0.74; specificity, 0.62) were independent diagnostic predictors for PF-ILD. In BALF, the NLR (cut-off 8.70, AUC 0.62; sensitivity 0.62; specificity 0.70), neutrophil count (cut-off 3.0, AUC 0.59; sensitivity 0.57; specificity 0.63), and lymphocyte count (cut-off 42.0, AUC 0.63; sensitivity 0.77; specificity 0.53) were independent diagnostic predictors. In PF-ILD patients (n = 77), lactate dehydrogenase (cut-off 275, AUC 0.69; sensitivity 0.57; specificity 0.78), Krebs von den Lungen-6 (cut-off 1,140, AUC 0.74; sensitivity 0.71; specificity 0.76), baseline forced vital capacity (FVC) (cut-off 1.75 L, AUC 0.71; sensitivity, 0.93; specificity, 0.46), and BALF neutrophil ratio (cut-off 6.0, AUC 0.72; sensitivity 0.79; specificity 0.80) correlated with death within 3 years. The BALF cellular ratio, particularly the neutrophil ratio, correlated with the diagnosis and prognosis of PF-ILD. These findings may be useful in the management of patients with interstitial pneumonia.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN PATIENTS WITH PROGRESSIVE FIBROSING AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES
    Maher, T.
    Bonella, F.
    Assassi, S.
    Noth, I.
    Diefenbach, C.
    Ittrich, C.
    Rohr, K.
    Kolb, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 722 - 722
  • [42] Effects of Nintedanib on Circulating Biomarkers in Subjects with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
    Maher, T. M.
    Jenkins, R. G.
    Bonella, F.
    Assassi, S.
    Diefenbach, C.
    Ittrich, C.
    Rohr, K. B.
    Kolb, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [43] Circulating biomarkers in children and adolescents with fibrosing interstitial lung disease (ILD)
    Deterding, Robin
    Brown, Kevin K.
    Cunningham, Steven
    Deboer, Emily M.
    Griese, Matthias
    Schwerk, Nicolaus
    Young, Lisa R.
    Ittrich, Carina
    Schlange, Thomas
    Gahlemann, Martina
    Warburton, David
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [44] Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease
    Alqalyoobi, Shehabaldin
    Adegunsoye, Ayodeji
    Linderholm, Angela
    Hrusch, Cara
    Cutting, Claire
    Ma, Shwu-Fan
    Sperling, Anne
    Noth, Imre
    Strek, Mary E.
    Oldham, Justin M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (02) : 250 - 253
  • [45] The Spectrum of Progressive Fibrosing Interstitial Lung Disease: Clinical and Managed Care Considerations
    Hamblin, Mark J.
    Kaner, Robert J.
    Owens, Gary M.
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (07): : S147 - S154
  • [46] Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study
    Sebastiani, Marco
    Venerito, Vincenzo
    Laurino, Elenia
    Gentileschi, Stefano
    Atzeni, Fabiola
    Canofari, Claudia
    Andrisani, Dario
    Cassone, Giulia
    Lavista, Marlea
    D'Alessandro, Francesco
    Vacchi, Caterina
    Scardapane, Arnaldo
    Frediani, Bruno
    Cazzato, Massimiliano
    Salvarani, Carlo
    Iannone, Florenzo
    Manfredi, Andreina
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (22)
  • [47] Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
    Lima Resende, Ana Carolina
    Mancuzo, Eliane Viana
    Soares, Maria Raquel
    Cavalcante Neto, Paulo Miranda
    Moreira, Maria Auxiliadora
    Neves Arantes, Leticia Ferreira
    Carlos Tibana, Regina Celia
    De Aguiar Baptista, Fernanda Maciel
    Galvao Nonato Alves, Tatiana Senna
    Storrer, Karin Mueller
    De Oliveira, Priscila Isolani
    Machado Nogueira, Fernanda Maria Pinheiro
    Martins, Rafaela Boaventura
    Krupok Matias, Simone Lobo
    Cordero Da Silva, Soraya Abou El Hosn
    Arida, Vanessa El Mir
    Botelho, Andre Bezerra
    De Moraes Beraldo, Bruno Leoncio
    Cunha Castro, Marina Dornfeld
    Fukuda, Cesar Yoshito
    Cerezoli, Milena Tenorio
    Ferreira, Rimarcs Gomes
    Missrie, Israel
    Pereira, Carlos
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [48] Prevalence of Progressive Fibrosing Interstitial Lung Disease in Patients with Primary Sjogren Syndrome
    Manfredi, Andreina
    Sambataro, Gianluca
    Rai, Alessandra
    Cerri, Stefania
    Sambataro, Domenico
    Vacchi, Caterina
    Cassone, Giulia
    Vancheri, Carlo
    Sebastiani, Marco
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [49] NATIONAL UK EXPERIENCE OF THE TREATMENT OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE WITH NINTEDANIB
    Dixon, G.
    Hague, S.
    Thould, H.
    Khin, A. M. N.
    Mulholland, S.
    Gibbons, M.
    Barratt, S. L.
    THORAX, 2023, 78 (SUPPL_4) : A11 - A12
  • [50] Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type
    Nili, Mona
    Steffens, Andrea
    Anderson, Amy
    Brekke, Lee
    Johnson, Mary Grace
    Veeranki, Phani
    Olson, Amy L.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (02): : 163 - 174